ExpreS2ion Biotech Holding AB (publ) (STO:EXPRS2)
Sweden flag Sweden · Delayed Price · Currency is SEK
14.78
-1.82 (-10.96%)
Feb 5, 2026, 5:29 PM CET

STO:EXPRS2 Cash Flow Statement

Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-45.17-36.04-91.4-118.61-43.93-31.71
Depreciation & Amortization
1.521.641.61.251.52.92
Other Operating Activities
0.85-23.77-2.393.339.12-0.29
Change in Accounts Receivable
1.05-2.058.63-8.19-1.35-0.34
Change in Other Net Operating Assets
-5.3326.29-17.3222.6-10.9911.25
Operating Cash Flow
-47.08-33.93-100.89-99.61-45.65-18.18
Capital Expenditures
-0-0.87-2.02-0.38-0.72-0.89
Sale (Purchase) of Intangibles
----0.05-
Investment in Securities
0.0422.15--0.68-0.19
Other Investing Activities
---105.71-100.93-
Investing Cash Flow
0.0421.28-2.02105.33-100.92-1.08
Short-Term Debt Issued
-----3.17
Long-Term Debt Issued
--1.47---
Total Debt Issued
-0.05-1.47--3.17
Short-Term Debt Repaid
----1.79-1.36-
Long-Term Debt Repaid
--0.12-3.86-0.52-0.62-0.42
Total Debt Repaid
-0.44-0.12-3.86-2.32-1.98-0.42
Net Debt Issued (Repaid)
-0.5-0.12-2.4-2.32-1.982.76
Issuance of Common Stock
10.1242.3460.7275.9683.3143.18
Other Financing Activities
-0.47-7.35-10.48-12.19-6.78-22.56
Financing Cash Flow
9.1534.8747.8461.4674.55123.38
Foreign Exchange Rate Adjustments
-1.631.731.696.692.3-2.71
Miscellaneous Cash Flow Adjustments
-----0-
Net Cash Flow
-39.5223.94-53.3873.86-69.72101.41
Free Cash Flow
-47.08-34.8-102.9-100-46.36-19.06
Free Cash Flow Margin
-433.87%-444.70%-1169.47%-1625.97%-337.66%-124.88%
Free Cash Flow Per Share
-18.46-20.58-89.19-113.97-63.42-43.96
Cash Interest Paid
0.050.140.632.721.193.14
Cash Income Tax Paid
--8.15-8.47-3.59-2.8-2.05
Levered Free Cash Flow
-37.05-17.96-75.61-68.69-37.71-14.99
Unlevered Free Cash Flow
-36.76-17.51-75.3-68.15-37.71-12.78
Change in Working Capital
-4.2824.24-8.714.41-12.3410.91
Source: S&P Global Market Intelligence. Standard template. Financial Sources.